The U.S. FDA Priority Review Voucher Read more
Counterfeit, Substandard and Generic Drugs: Distinct Definitions for Distinctly Different Problems Read more
Valganciclovir Patent Set Aside in India read MSF's statement
New MSF report shows Europe failing to pay fair share of TB research
MSF hosts malnutrition symposium in NY Read more
|
 |
|
 |
|
 |
HIV AIDS
|
 |
© MSF |
There are an estimated 2.1 million children living with HIV/AIDS, 90% of whom are from sub-Saharan Africa. Only 10% receive any treatment for the disease.
To read our press release about children and HIV/AIDS for World AIDS Day click hereNine out of ten children are denied live-saving HIV/AIDS treatment
Too many children with HIV/AIDs still waiting
To read a mother and son's account of living with HIV/AIDS click here To find out more about HIV in general click here PMTCT: Overcoming the Obstacles
In June, MSF held an Experts Roundtable in Geneva to discuss the current limitations of prevention of mother-to-child transmission (PMTCT) programmes in the developing world and explore ways of improving the current WHO recommendations Find out more Untangling the Web 11th Edition
MSF presents the findings from the 11th edition of UTW at the IAC in Mexico: higher prices for newer ARVs, inadequate paediatric treatments and the newest therapies only for the West. Read more For full details of MSF at the IAC Click here 'Running in Place' MSF's full briefing paper on the challenges of treating HIV/AIDS for the IAC Click here |
Fair treatment for children living with HIV
Treating children and adolescents living with HIV effectively in resource-limited settings is possible, but adapted medicines, diagnostic tools, and treatment strategies are urgently needed to prevent more deaths. Read MSF press release at the IAC in Mexico
Fighting for better drugs
Dr Johan van Grievsen, an HIV doctor in Rwanda with MSF until the end of 2007, describes the severe side effects of some antiretrovirals drugs and why patients need access to a better drug - tenofovir - but at an affordable price.
|
Developing drugs for developing countries
MSF authors argue that drug companies need to ensure the needs of patients in developing countries are integrated into drug development plans.
|
